Navigation Links
WorldHeart Appoints Dr. John Campbell Woodard as Senior Vice President of Scientific Affairs
Date:4/30/2010

SALT LAKE CITY, April 30 /PRNewswire-FirstCall/ -- World Heart Corporation (WorldHeart; Nasdaq: WHRT), a developer of mechanical circulatory systems, announced the appointment of Dr. John Campbell Woodard as Senior Vice President of Scientific Affairs. Dr. Woodard will be responsible for clinical affairs and will also guide the development of World Heart's next- generation technologies. Dr. Woodard most recently served as Chief Scientific Officer for Ventracor Limited: an Australian-based public company focused on the development of left ventricular assist devices for late-stage heart failure patients. Prior to that, Dr. Woodard has served in various senior management positions in a number of medical device companies including, Micromedical Industries Limited, CHAD Research Laboratories, Novacor Division of Baxter Healthcare Corporation and Heart Research Institute of San Francisco.

Dr. Woodard's educational accomplishments include a Bachelor in Electrical Engineering, a Master of Science in Biophysics and a Doctor of Philosophy in Biomedical Engineering at the University of South Wales.  Dr. Woodard has been awarded over 14 medical device related patents and he has authored numerous peer-reviewed papers and abstracts.

J. Alex Martin, President and CEO of WorldHeart commented, "We are extremely pleased to have a well recognized and respected leader in the field of Mechanical Circulatory Support join WorldHeart. We look forward to John's contributions to our efforts to serve patients suffering from advanced heart failure."

Jal S. Jassawalla, Executive Vice President and Chief Technology Officer added, "I'm delighted to welcome John back and look forward to having him be part of the WorldHeart team."

Dr. Woodard will relocate to WorldHeart's corporate headquarters in Salt Lake City, Utah with an anticipated start date of May 17, 2010.

About the Levacor VAD and World Heart Corporation

The Levacor VAD is the only fully magnetically levitated, bearingless, implantable centrifugal pump to move into clinical trial.  By using magnetic levitation to fully suspend a spinning rotor, the Levacor VAD's only moving part, the pump is designed to eliminate wear and to provide unobstructed clearances for blood flow across a wide range of operation.

WorldHeart is a developer of mechanical circulatory support systems based in Salt Lake City, Utah with additional facilities in Oakland, California, USA. WorldHeart's registered office is in Delaware, USA.

Any forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include all statements relating to WorldHeart's reliance on key executive officers, its BTT clinical study of the Levacor VAD, strategic direction, increase in shareholder value, access to investment capital, its clinical development programs and the product pipeline, and the growth of WorldHeart's overall business, as well as other statements that can be identified by the use of forward-looking language, such as "believes," "feels," "expects," "may," "will," "should," "seeks," "plans," "anticipates," or "intends" or the negative of those terms, or by discussions of strategy or intentions. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including without limitation: risks involved in the clinical trials of the Levacor VAD; reliance on key executive officers; WorldHeart's need for additional capital in the future; risks in product development, regulatory approvals and market acceptance of and demand for WorldHeart's products; and other risks detailed in WorldHeart's filings with the U.S. Securities and Exchange Commission, including without limitation its Annual Report on Form 10-K  for the year ended December 31, 2009.

www.worldheart.com


'/>"/>
SOURCE World Heart Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
2. WorldHeart Receives US Clinical Study Approval for the Levacor(TM) VAD
3. WorldHeart Receives IRB Approval at First Center in the Levacor(TM) VAD BTT Clinical Trial
4. WorldHeart Announces First U.S. Implant of Levacor(TM) VAD Implant at INTEGRIS in Oklahoma City
5. WorldHeart Receives Unconditional BTT Study Approval From FDA for Levacor(TM) VAD
6. WorldHeart Signs Agreements for Next-Generation Minimally Invasive Blood Pump
7. NASDAQ Stock Market Confirms WorldHearts Compliance With NASDAQ Listing Rule 5605
8. WorldHeart Reports 2009 Financial Results
9. Quark Pharmaceuticals Appoints New Chief Medical Officer
10. West Pharmaceutical Services, Inc. Appoints New Director
11. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... May 4, 2016 Valeritas Holdings, ... an alternative public offering (APO). This was accomplished via ... Valeritas, Inc. and a private placement of approximately 5 ... per share. Under the terms of the ... Valeritas Holdings, Inc. will trade on the OTC Markets ...
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Actinic Keratosis Market ... to their offering.       (Logo: ... Keratosis Market and Competitive Landscape Highlights 2016, ... products, Actinic Keratosis epidemiology, Actinic Keratosis market ...
(Date:5/3/2016)... , May 4, 2016 Research ... "Global Cancer Stem Cell Therapy Market Outlook 2020" ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,Recombinant technology has improved significantly ... expected to be developed in coming years. Many cancer ... Cancer stem cell therapies are also expected to be ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... ... of commercial real estate proudly announced that its service-based charitable program, Olshan Outreach, ... members portfolio-wide will continue Olshan Properties’ annual philanthropic tradition in 2016 with the ...
(Date:5/4/2016)... Columbia, MD (PRWEB) , ... May 04, 2016 ... ... Wound, Ostomy and Continence Nurses (WOCN) Society™ and Canadian Association for Enterostomal ... matchmaking, event promotion, time saving and planning tools to attendees and exhibitors for ...
(Date:5/4/2016)... ... 2016 , ... All-Star Insurance of Northeast TX has announced ... their local community. The agency pledges to select a new beneficiary every 60 ... bring awareness to important local causes with fundraising and other support, by forming ...
(Date:5/4/2016)... Island (PRWEB) , ... May 04, 2016 , ... ... in April 2016. SS&A teamed up with one of the top website design ... information portal contains informative legal articles related to the law firm's main practice ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... foundational nutrients that supports cellular and metabolic health. This synergistic combination of omega-3 ... free-form curcumin, along with 150 mg of reduced glutathione and 200 mg of ...
Breaking Medicine News(10 mins):